FierceBiotech is a free daily email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals, and more. It serves as the biotech industry's daily monitor for more than 90,000 biotech professionals. FierceBiotech’s client base includes senior business executives and clinical operations leaders at biotech, pharmaceuticals, and related drug development companies. It provides information related to clinical stage drug development, FDA and EMEA regulations, drug licensing pacts, mergers and acquisitions involving developers, and biotech and pharma deals. FierceBiotech is based in Washington.

FierceBiotech

Pharma Now is a monthly B2B magazine that covers trends, technological innovations, and insights in the pharmaceutical and biopharmaceutical sectors. It provides industry news and updates, interviews with leaders, market insights, and regulatory updates.

Pharma Now

Fierce Pharma covers the pharma waterfront, from late-stage drug development through the entire lifecycle—tracking regulatory approvals, payer negotiations, manufacturing, marketing, patent fights, government investigations and regulation, M&A deals and beyond.

Fierce Pharma

This week on 'The Top Line', if you missed the Clinical Trials on Alzheimer’s Disease conference, catch up with our analysis of the biggest readouts. Plus, we cover the week's news including an investigation into Neuralink, Google’s DeepMind and more.

After a positive opinion from regulators back in October, Takeda's dengue vaccine scored a green light from the European Commission. The approval sets up potential nods in other endemic countries.

The odd saga of Oncopeptides' multiple myeloma drug—thriving in Europe while sidelined in the U.S.—continued Wednesday with the FDA requesting a withdrawal of the U.S. marketing authorization for Pepaxto.

Plaintiffs in the now-dismissed clutch of cases argued Merck's vaccine Zostavax caused their shingles. But the medical expert attempting to back up that claim failed to consider whether plaintiffs’ disease occurred naturally because they’d had chickenpox as kids, according to court filings published this week.

On ICER’s annual list of drugs that had unjustified price increases in 2021, Bausch’s Xifaxan and Johnson & Johnson’s Invega Sustenna caused the most additional spending in the U.S. The treatments displaced Humira as the top offender in 2020.

GSK's emerging oncology business just got a much-needed boost after several recent setbacks. A first glimpse at its PD-1 inhibitor's head-to-head data against Keytruda looks encouraging.

In an investigator-initiated phase 2 study of Enhertu in neoadjuvant HER-2 low breast cancer, just one patient achieved the trial's “tried and true” pre-surgery endpoint of pathologic complete response, Daiichi’s clinical oncology chief Mark Rutstein said in an interview ahead of the 2022 San Antonio Breast Cancer Symposium.

When Eli Lilly’s Verzenio snagged an FDA go-ahead to treat certain breast cancer patients after surgery, the first-in-class nod was weakened by an unexpected limitation. Now, the company hopes longer-term follow-up data will convince U.S. regulators to remove the restriction.

Metric
Company Name	FierceBiotech	Pharma Now
Symbol
MSH ID	COM:FIERCEBIOTECH	LIVE:PHARMANOW
Market	PRIVATE	PRIVATE
Sector	Healthcare	Consumer Services
Industry	Biotech	Pharmaceuticals
Country	US	IN
Stage
Employee Count	51
Website	fiercebiotech.com	pharmanow.live
LinkedIn	fierce-pharma	pharma-now
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:FIERCEBIOTECH

FierceBiotech

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue